Drug Trial Radar · NCT07917910
A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Oct 30, 2028
Study completion Sep 17, 2029
Sponsor
- Lead sponsor
- Suzhou HepaThera Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II trial of HT-101 + HT-102 in CHB: (1) functional cure in treatment-naïve patients (vs placebo); (2) efficacy of sequential interferon in previously treated patients.
Conditions
- Chronic Hepatitis B Virus Infection
Interventions
HT-101 + HT-102Drug
HT-101 given by subcutaneous injection.HT-102 given by subcutaneous injection.
HT-101 placebo + HT-102 placeboDrug
HT-101 placebo + HT-102 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving functional cure at Week 24 of follow-up after discontinuation of all anti-hepatitis B medications.Time frame: Up to Week 72
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.